Dosimetric results in treatments of neuroblastoma and neuroendocrine tumors with (131)I-metaiodobenzylguanidine with implications for the activity to administer.

Research output: Contribution to journalArticle

Abstract

The aim was to investigate whole-body and red marrow absorbed doses in treatments of neuroblastoma (NB) and adult neuroendocrine tumors (NETs) with (131)I-metaiodobenzylguanidine and to propose a simple method for determining the activity to administer when dosimetric data for the individual patient are not available.

Details

Authors
Organisations
External organisations
  • Gurutzeta/Cruces University Hospital
  • Royal Marsden NHS Foundation Trust
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Radiology, Nuclear Medicine and Medical Imaging
Original languageEnglish
Pages (from-to)3969-3978
JournalMedical Physics
Volume42
Issue number7
Publication statusPublished - 2015
Publication categoryResearch
Peer-reviewedYes

Total downloads

No data available